Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Weleader Biomedical CoROCO:7713 42 FCF Margin % is 16.42% as of Mar. 2026, which is 43% above its 10-year median of 11.45. GuruFocus rates ROCO:7713 with a GF Score™ of 42/100. The stock has 5 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Weleader Biomedical Co ranks better than 75.15% on this metric.
The historical rank and industry rank for Weleader Biomedical Co's FCF Margin % or its related term are showing as below:
ROCO:7713'
s FCF Margin % Range Over the Past 10 Years
Min: -36.82 Med: 11.45 Max: 25.46
Current: 10.26
During the past 6 years, the highest FCF Margin % of Weleader Biomedical Co was 25.46%. The lowest was -36.82%. And the median was 11.45%.
ROCO:7713's FCF Margin % is ranked better than 75.15% of 813
companies
in the Medical Devices & Instruments industry
Industry Median: -0.96
vs ROCO:7713: 10.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7713 vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, Weleader Biomedical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Weleader Biomedical Co FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Weleader Biomedical Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Weleader Biomedical Co (ROCO:7713) has a FCF Margin % of 16.42% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Weleader Biomedical Co and its competitors. This is 43% above median its historical median of 11.45. According to the industry distribution chart, Weleader Biomedical Co ranks #202 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 24.8%.
Is Weleader Biomedical Co's FCF Margin % too high?
Weleader Biomedical Co's current FCF Margin % of 16.42% is 43% above median its 10-year median of 11.45. Based on the distribution chart, Weleader Biomedical Co ranks #202 out of 813 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Weleader Biomedical Co has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #202 out of 813 companies for FCF Margin %. This places Weleader Biomedical Co in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Weleader Biomedical Co and its competitors. Weleader Biomedical Co's current FCF Margin % is 16.42%, which is 43% above median its own 10-year median of 11.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current FCF Margin % of 16.42%. The current FCF Margin % is 16.42%, which is 43% above median its 10-year median of 11.45. Weleader Biomedical Co's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current FCF Margin % is 16.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
42GF Score
Get the complete analysis for ROCO:7713
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
